Regeneron, Ultragenyx collaborate to commercialize Evkeeza outside U.S.
Kelvin Murray/DigitalVision via Getty Images


Regeneron Pharmaceuticals (NASDAQ:REGN) and Ultragenyx Pharmaceutical (NASDAQ:RARE)
announce a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and distribute Evkeeza (evinacumab) in countries outside of U.S.
Under the terms of the agreement, Regeneron will receive a $30M upfront payment and is eligible to receive up to $63M in additional milestone payments.

Ultragenyx will receive the rights to develop, commercialize and distribute the medicine in countries outside U.S. and make payments to Regeneron based on net sales.
Regeneron has also granted RARE an exclusive option to negotiate a separate agreement to collaborate on the development of its investigational antibody currently in Phase 2/3 development outside U.S., for the treatment of the ultra-rare disease, fibrodysplasia ossificans progressiva under terms to be agreed upon by both companies.